Yuzu Labs
Yuzu Labs is a company.
Financial History
Leadership Team
Key people at Yuzu Labs.
Frequently Asked Questions
Who founded Yuzu Labs?
Yuzu Labs was founded by Eron Villarreal (Co-Founder).
Yuzu Labs is a company.
Key people at Yuzu Labs.
Yuzu Labs was founded by Eron Villarreal (Co-Founder).
Yuzu Labs was founded by Eron Villarreal (Co-Founder).
Key people at Yuzu Labs.
Yuzu Labs PBC is a portfolio company building StudyPages, a patient recruitment and engagement platform for clinical research that intersects software, web/mobile technology, and clinical science.[1] It serves academic medical centers, private clinics, contract research organizations (CROs), and pharmaceutical companies, solving the major bottleneck of study recruitment to reduce costs and timelines in clinical development by connecting participants, academia, and industry.[1][3] The platform enables participant-centric research through tools like digital consent collection, electronic signatures, clinical trial management, patient onboarding, and AI-driven engagement, with reported revenue around $5 million and a small team of 7-11 employees.[2][3][5]
Founded in 2014 in the San Francisco Bay Area (with addresses in San Francisco and San Jose, California), Yuzu Labs emerged from a focus on rethinking clinical, behavioral, and social research to make it more accessible, faster, and cheaper by prioritizing participants.[1][3][5] Co-founders Eron Villarreal, a software developer with Silicon Valley experience in startups, search, mobile advertising, electronic medical records, and medical devices, and Koen De Lombaert, MD MBA with a medicine and business background (born in Belgium, US-based since 2011), drive the company.[1][3] Early traction centered on co-designing mobile and web solutions with patients, researchers, industry leaders, and thought leaders to put participants at the core, evolving from general research tools to specialized clinical trial optimization.[1][5]
(Note: A separate entity at yuzulabs.io focuses on AI video tools with different YC-alum founders; this analysis centers on the clinical research Yuzu Labs PBC.[2])
Yuzu Labs rides the trend of digital transformation in clinical trials, where recruitment delays—often the biggest hurdle—cost billions amid rising demand for faster drug development post-pandemic.[1] Timing aligns with growth in decentralized trials, AI for patient matching, and telehealth, fueled by market forces like pharma's push for efficiency and regulatory support for digital tools.[1][5] By enabling participant-centered ecosystems, it influences the startup scene in healthtech/biotech, competing with platforms in clinical CRM and recruitment while fostering co-design models that could standardize patient involvement across the $50B+ clinical research market.[1][3]
Yuzu Labs is poised to expand as AI and decentralization reshape clinical research, potentially scaling StudyPages through partnerships with big pharma or CROs amid ongoing trial backlogs. Trends like AI-driven matching and real-world data integration will boost its momentum, evolving its influence from niche optimizer to ecosystem leader in patient-centric trials. With proven revenue traction since 2014, expect growth via enterprise adoption, tying back to its core mission of slashing clinical development timelines.[1][3]